What risks are associated with using MRAs in patients with heart failure?
The potential risks associated with using MRAs in patients with heart failure include hyperkalaemia, renal impairment, and gynaecomastia. These risks can be managed by starting patients on appropriate doses, measuring patients potassium levels and renal function at baseline and monitoring those levels regularly, and appropriate dose adjustment. Clinicians should also consider switching to eplerenone in patients who experience gynaecomastia while taking spironolactone.